openPR Logo
Press release

The Growth Factors Market to look through AI-based genomics at a CAGR of 6.9%

03-02-2023 09:04 PM CET | Health & Medicine

Press release from: Persistence Market Research

The Growth Factors Market to look through AI-based genomics at

The global Growth Factors Market is all set to witness a CAGR of 7.2% in the next decade. It is expected to reach US$ 3.6 Bn by the year 2031. With digitized communication channels making a beeline to the healthcare vertical, the advanced clinics are into virtual consultation mode, and this scenario is expected to continue even going forward. Regulatory approvals for this type of communication are on the way. Close to 70% of the public hospitals worldwide are being asked to adopt digital means. This would be the scene with the healthcare vertical in the subsequent period.

Growth factors are proteins that stimulate cell division and growth, as well as differentiation and survival. They play an essential role in the development and regeneration of tissues in the body. The growth factors market includes a wide range of products that are used in various research and clinical applications. The market has been growing rapidly over the years due to the increasing prevalence of chronic diseases, rising demand for regenerative medicines, and the growing biotechnology and pharmaceutical industries.

As per Persistence Market Research's latest revised industry analysis, the global growth factors market was valued at over US$ 1.7 Bn in 2020, and is expected to exhibit a CAGR of close to 7% over the forecast period (2021-2031).

Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/4456

According to the World Health Organization (WHO), cancer caused around 9.9 million deaths worldwide in 2020. In addition, around 19.2 million people across the world were suffering from cancer. Also, increasing occurrence of autoimmune disorders is anticipated to drive demand for growth factors.

Rising prevalence of autoimmune diseases and cancer and the benefits of cytokine and growth factors therapy in the treatment of these diseases are expected to complement market growth over the coming years.

Growing research in the field of wound healing and skin regeneration is also expected to favor expansion of the global growth factors market. However, high cost associated with GMP grade growth factors is estimated to hamper market growth.

Acquisitions, collaborations, and partnership agreements are rife in this landscape:

PPD, Inc., a leading clinical research organization, was acquired by Thermo Fisher Scientific in April 2021, expanding the company's service offerings to pharma and biotech customers.

Merck and BioMed X Institute extended their collaboration to continue novel oncology and autoimmunity research in 2021.

In 2021, Lonza and ValenzaBio entered into a manufacturing agreement to rapidly advance VB421, an anti-IGF-1R antibody for autoimmune diseases.

Company Profiles:

Thermo Fisher Scientific
Lonza Group AG
Merck KGaA
General Electronics Company
F. Hoffmann-La Roche Ltd
Applied Biological Materials (abm), Inc.
Abcam plc.
Cell Signaling Technology, Inc.
Meridian Bioscience Inc.
Sartorius CellGenix GmbH
Bio-Techne.
Proteintech Group, Inc.
Miltenyi Biotec
Creative Bioarray
Akron Biotech
Sino Biological Inc.
Repligen corporation
LEADGENE BIOMEDICAL, INC.
PeproTech Inc.
Others

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/4456

Key Takeaways from Market Study

By grade, NON-GMP grade products hold around 70% market value share, globally, primarily due to increasing focus on oncology research and growing contract research activities.

Based on product, interleukins are leading with over 21% market share. Strong product pipelines by various key players are positively driving demand for interleukins among growth factor products.
Cell therapy and ex vivo manufacturing are estimated to dominate the market by application. This segment accounted for approximately 29% share of the market, primarily due to increase in acceptance of growth factors in cancer and autoimmune therapies

Pharmaceutical and biotechnology companies dominate with a market share of 48%. Growing number of R&D activities and increasing preference toward growth factors for gene therapy have had a positive impact on the market.

North America is set to dominate the global market with a value share of around 41%. Europe is slated to be the second-largest region with a value share of 30%.

"Rising prevalence of cancer, preference toward use of regenerative medicines, and new product launches & approvals are expected to drive market growth over the coming years," says an analyst of Persistence Market Research.

Demand-side Drivers:

Increasing focus on oncology research
Growing demand for growth factors and cytokines in stem cell biology
Increasing demand for growth factors in regenerative medicine

Market Opportunities:

Shift toward fast growing Asia Pacific market
Limited number of companies with sole focus on GMP grade products.

Market Competition

New product approvals, launches, collaborations, agreements, and partnerships have emerged as the main growth strategy implemented by leading players. By focusing on these strategies, key market players are strengthening their existing product portfolios to expand their geographic footprints.

In 2020, the humankind human cell-expressed growth factor of Proteintech Group, Inc received an ISO 13485 Certificate.
In 2020, Akron Biotech signed an agreement to acquire Cytiva. This acquisition helps enhance its cGMP-compliant solutions and support the development of advanced therapy.

For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/4456

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the growth factors market in its latest study, presenting a historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.

The research study is based on the product (transforming growth factors (TGF), epidermal growth factors (EGFs), platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), insulin-like growth factors (IGFs), vascular endothelial growth factors (VEGFs), hepatocyte growth factors (HGFs), tumour necrosis factors (TNFs), interleukins, and others), grade (GMP grade and NON-GMP grade), application (oncology research, haematology research, wound healing research, dermatology research, cardiovascular disease & diabetes, cell therapy and ex vivo manufacturing, and others), and end user (pharmaceutical and biotechnology companies, research centres & academic institutes, and CMOs & CDMOs), across seven key regions of the world.

Related Reports:

Telemedicine Market :
https://www.persistencemarketresearch.com/market-research/telemedicine-market.asp

Robotic Surgery Market:
https://www.persistencemarketresearch.com/market-research/robotic-surgery-market.asp

Veterinary Teleradiology Market:
https://www.persistencemarketresearch.com/market-research/veterinary-teleradiology-market.asp

Dental Radiology Equipment Market:
https://www.persistencemarketresearch.com/market-research/dental-radiology-equipment-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Growth Factors Market to look through AI-based genomics at a CAGR of 6.9% here

News-ID: 2958414 • Views:

More Releases from Persistence Market Research

Dental Infection Control Products Market Sees Robust Growth, Says Persistence Market Research
Dental Infection Control Products Market Sees Robust Growth, Says Persistence Ma …
The global dental infection control products market is experiencing robust growth, fueled by the rising need for hygiene and infection prevention in dental care. According to Persistence Market Research, the industry is set to expand from a valuation of US$1.7 billion in 2024 to US$2.9 billion by 2031, reflecting a strong CAGR of 7.2%. Increasing demand for sterilization equipment, disinfectants, and protective gear underscores the central role of infection control
mRNA Synthesis and Manufacturing Market Growth Forecast by Persistence Market Research
mRNA Synthesis and Manufacturing Market Growth Forecast by Persistence Market Re …
The mRNA synthesis and manufacturing market has emerged as one of the most dynamic sectors within the biopharmaceutical industry. With applications spanning from vaccines to personalized medicine, the demand for scalable, cost-effective, and high-quality mRNA production has surged significantly. According to Persistence Market Research, the global market is projected to rise from US$52.7 billion in 2023 to US$64.4 billion by 2031, expanding at a CAGR of 2.5% during 2024-2031. The primary
Filtered Hearing Protection Devices Market Growth Opportunities and Challenges Explored by Persistence Market Research
Filtered Hearing Protection Devices Market Growth Opportunities and Challenges E …
The filtered hearing protection devices market is gaining rapid momentum as rising industrialization, recreational activities, and awareness about noise-induced hearing loss drive adoption. According to Persistence Market Research, the global market is projected to grow from US$866.9 million in 2024 to US$1.6 billion by 2031, advancing at a CAGR of 8.7%. This strong growth trajectory reflects the increasing demand for advanced hearing protection solutions that balance safety with user comfort
Sinus Dilation Devices Market Demand Forecast and Key Drivers by Persistence Market Research
Sinus Dilation Devices Market Demand Forecast and Key Drivers by Persistence Mar …
The global sinus dilation devices market has been witnessing steady growth, supported by rising cases of chronic sinusitis and an increasing preference for minimally invasive surgical procedures. According to Persistence Market Research, the market is projected to expand from US$2.97 Bn in 2024 to US$4.50 Bn by 2031, advancing at a CAGR of 6.1%. The market has already recorded a historical CAGR of 5.5% between 2019 and 2023, signaling a

All 5 Releases


More Releases for GMP

Creative Peptides Released GMP Synthesis Service
Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides. As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more
Diapharm implements European GMP guidelines in China
Münster (DE), London (UK), Ningbo (CN), 20 December 2013 – Pharmaceutical service provider Diapharm (diapharm.com) is increasing its business activities in China: Diapharm has now implemented a “European” quality management system for Neptune Pharma Ltd (www.neptunepharma.com) in their Joint Venture Partner’s factory in Ningbo, Zhejiang Province. And it has done so successfully: The veterinary medicinal product Trident 500mg/g Powder for Suspension for Fish Treatment (www.trident-50.com), is manufactured onsite under EU
ECA Foundation releases free GMP WebApp
The ECA Foundation has been providing advanced training and information services in the pharmaceutical industry and especially with regard to pharmaceutical Quality Assurance and GMP compliance for more than 10 years. Now the organisation took advantage of its extensive experience to develop a further free of charge service – the new GMP WebApp. This new GMP WebApp runs on all smartphones and tablet PCs (Apple and Android platforms) and allows users
GMP Friction Products Awarded ISO 9001:2008
Internationally Recognized Certification Measures Consistency in Process, Procedure and Quality Performance in Manufacture of Friction Materials AKRON, OH (March 23, 2011) -- GMP Friction Products, a world leader manufacturing powdered metal friction products for clutch plates and brake pads, recently received certification for ISO 9001:2008. “ISO 9001:2008 signifies we have taken the extra measure of documenting the policies and standards to ensure consistent compliance with our manufacturing processes,” said Jerry Lynch,
GMP MANUAL Volume 2 - Validation Procedures by Maas & Peither AG – GMP Publish …
GMP Publishing is launching its new GMP MANUAL Volume 2 – Validation Procedures. The compendium on validation procedures was written by Dr. Doris Borchert, Dr. Peter Bosshard, Dr. Ralph Gomez, Dr. Michael Hiob, Dr. Christine Oechslein, Max Lazar, Ulrike Reuter, Michael Schulte, Uwe Schwarzat – all international experts and key opinion leaders. They share their detailed understanding of the various aspects of the validation process in clear and comprehensive style
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009. Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body,